Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer

© 2023 by the Society of Nuclear Medicine and Molecular Imaging. Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications. License: https://creativecommons.org/licenses/by/4.0/. Details: http://jnm.snmjournals.org/site/misc/permission.xhtml.

Author Information

¹Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida;
²Participant Research, Interventions, and Measurements Core, Moffitt Cancer Center, Tampa, Florida;
³Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California;
⁴Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, Florida;
⁵Department of Nuclear Medicine, University of Duisburg–Essen, and German Cancer Consortium–University Hospital Essen, Essen, Germany;
⁶Departments of Medical Social Sciences and Psychiatry and Behavioral Sciences, and Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois;
⁷Prostate Cancer Theranostics and Imaging Centre of Excellence, Cancer Imaging, Peter MacCallum Centre, Melbourne, Victoria, Australia, and MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia;
⁸Department of Pharmacology and Experimental Therapeutics, Sidney Kimmel Cancer, Thomas Jefferson University, Woodbury, New Jersey; and
⁹Department of Urology, Weill Cornell Medical College, New York, New York

For correspondence or reprints, contact Lisa M. Gudenkauf (lisa.gudenkauf{at}moffitt.org).